Close this search box.

MyAccuray: VOLO™ Ultra, a New Way of Planning with Accuray Precision® Treatment Planning System, Architected to Accelerate Radixact® and TomoTherapy® Treatments

August 30, 2021

This year at ESTRO, Accuray is unveiling the latest in our leading legacy of innovation that empowers clinicians to deliver more, better, faster: VOLO Ultra. Kai Schubert will share his preliminary insights with the simplicity of planning, excellent plan quality and transformative speed for TomoTherapy® System treatments. 

VOLO Ultra was applied retrospectively to existing patient cases. No patients were treated with the resulting plans.

Kai Schubert, Ph.D., Universität Klinikum Heidelberg, Heidelberg, Germany

Dr. Kai Schubert studied Physics at the Heidelberg University and graduated in 1995. After this he entered the field of radiation therapy at the Heidelberg University Hospital, where he is still working. 1999 he got a PhD in medical physics from the Heidelberg University. In 2004 and 2005 he was head of medical physics at the Al Amal Hospital in Doha (Qatar), where a radiation therapy service was established in collaboration with Heidelberg University.

Madhavi Kapa, Senior Director of Product Strategy, Accuray Incorporated

Madhavi Kapa is the Senior Director of Product Strategy at Accuray Incorporated, responsible for Radixact/TomoTherapy product portfolio. She has knowledge of multiple medical technologies in diagnosis and treatment along with extensive healthcare business experience in product management, roadmap planning, product creation and launch. Prior to joining Accuray, she has over 15 years of experience with Philips, leading Radiation Oncology Simulation and Treatment planning applications and working on advanced visualization and PACS solutions. Madhavi has been with Accuray for about 4 years and leads the product strategy for Accuray’s helical treatment delivery solutions.

Moderated by: Philippe Degreze, VP Downstream Marketing & Communication Channels, Accuray Incorporated

Philippe Degreze has a PhD in biomathematics and modelisation. From his first experience as engineer in a University Hospital to his career at GE Healthcare, and then at Accuray, Philippe always worked to commercialize high-tech products for the benefits of patients. From his career in imaging and in magnetic resonance at GE Healthcare to radiation therapy Philippe was involved in sales, product management and is currently leading the global downstream marketing effort of Accuray.

Work in progress. VOLO Ultra Option for Accuray Precision® Treatment Planning System availability is pending development and regulatory clearance or approval.

Important Safety Information:
Most side effects of radiotherapy, including radiotherapy delivered with Accuray systems, are mild and temporary, often involving fatigue, nausea, and skin irritation. Side effects can be severe, however, leading to pain, alterations in normal body functions (for example, urinary or salivary function), deterioration of quality of life, permanent injury and even death. Side effects can occur during or shortly after radiation treatment or in the months and years following radiation. The nature and severity of side effects depend on many factors, including the size and location of the treated tumor, the treatment technique (for example, the radiation dose), the patient’s general medical condition, to name a few. For more details about the side effects of your radiation therapy, and to see if treatment with an Accuray product is right for you, ask your doctor.